American Renal Associates (ARA) Upgraded by Zacks Investment Research to “Buy”

Share on StockTwits

Zacks Investment Research upgraded shares of American Renal Associates (NYSE:ARA) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning. They currently have $22.00 price objective on the stock.

According to Zacks, “American Renal Associates Holdings, Inc. is a provider of dialysis services primarily in the United States. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure. American Renal Associates Holdings, Inc. is based in Beverly, Massachusetts. “

Other research analysts have also recently issued reports about the stock. Bank of America reduced their target price on shares of American Renal Associates from $25.00 to $21.00 and set a buy rating on the stock in a research report on Tuesday, July 10th. SunTrust Banks reissued a buy rating and set a $25.00 target price on shares of American Renal Associates in a research report on Thursday, August 9th. ValuEngine raised shares of American Renal Associates from a hold rating to a buy rating in a research report on Friday, August 3rd. Goldman Sachs Group initiated coverage on shares of American Renal Associates in a research report on Thursday, July 19th. They set a neutral rating and a $16.00 target price on the stock. Finally, Leerink Swann raised shares of American Renal Associates from a market perform rating to an outperform rating and boosted their target price for the stock from $22.00 to $26.00 in a research report on Thursday, August 23rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $22.60.

NYSE ARA opened at $18.96 on Tuesday. American Renal Associates has a 52 week low of $9.91 and a 52 week high of $24.07. The company has a debt-to-equity ratio of 5.30, a quick ratio of 1.04 and a current ratio of 1.07. The firm has a market cap of $702.91 million, a PE ratio of 31.18, a PEG ratio of 3.83 and a beta of 2.51.

American Renal Associates (NYSE:ARA) last posted its earnings results on Tuesday, August 7th. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.17 by $0.03. American Renal Associates had a negative net margin of 1.11% and a positive return on equity of 19.60%. The business had revenue of $217.18 million for the quarter, compared to analysts’ expectations of $203.70 million. As a group, equities research analysts anticipate that American Renal Associates will post 0.6 earnings per share for the current year.

Several large investors have recently modified their holdings of ARA. Rhumbline Advisers bought a new stake in shares of American Renal Associates in the second quarter worth $195,000. Element Capital Management LLC bought a new stake in shares of American Renal Associates in the first quarter worth $263,000. Macquarie Group Ltd. increased its stake in shares of American Renal Associates by 1,867.7% in the second quarter. Macquarie Group Ltd. now owns 20,700 shares of the company’s stock worth $326,000 after buying an additional 19,648 shares during the last quarter. A.R.T. Advisors LLC bought a new stake in shares of American Renal Associates in the first quarter worth $354,000. Finally, Paloma Partners Management Co bought a new stake in shares of American Renal Associates in the second quarter worth $356,000. Institutional investors and hedge funds own 93.25% of the company’s stock.

American Renal Associates Company Profile

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Further Reading: How to Invest in the Dividend Aristocrat Index

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply